ECO Animal Health Group (LON:EAH) Stock Price Passes Above 50 Day Moving Average – Here’s What Happened

ECO Animal Health Group plc (LON:EAH)’s stock price passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 101.85 and traded as high as GBX 113. ECO Animal Health Group shares last traded at GBX 109.45, with a volume of 39,427 shares traded.

Analyst Upgrades and Downgrades

Separately, Shore Capital upped their target price on shares of ECO Animal Health Group from GBX 150 to GBX 160 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of GBX 160.

ECO Animal Health Group Stock Performance

The company has a debt-to-equity ratio of 4.81, a quick ratio of 2.14 and a current ratio of 2.96. The stock has a 50 day moving average of GBX 102.47 and a 200 day moving average of GBX 87.47. The stock has a market capitalization of £68.09 million, a P/E ratio of 23.12 and a beta of -0.05.

ECO Animal Health Group (LON:EAH) last released its quarterly earnings data on Monday, December 1st. The company reported GBX (0.54) earnings per share for the quarter. ECO Animal Health Group had a return on equity of 1.27% and a net margin of 1.17%.

Insider Activity at ECO Animal Health Group

In related news, insider David Hallas bought 18,348 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was purchased at an average price of GBX 109 per share, for a total transaction of £19,999.32. Company insiders own 11.14% of the company’s stock.

About ECO Animal Health Group

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.